home / stock / gud:cc / gud:cc news

GUD:CC News and Press, Knight Therapeutics Inc. From 10/07/25

Stock Information
Company Name: Knight Therapeutics Inc.
Stock Symbol: GUD:CC
Market: TSXC
Website: gud-knight.com
Menu
GUD:CC GUD:CC Quote GUD:CC Short GUD:CC News GUD:CC Articles GUD:CC Message Board
Get GUD:CC Alerts

News, Short Squeeze, Breakout and More Instantly...
GUD:CC - Knight Therapeutics Announces Relaunch of MYFEMBREE® in Canada

MONTREAL, Oct. 07, 2025 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc., (TSX: GUD) (“Knight”) a pan-American (ex-USA) specialty pharmaceutical company, announced today that it has relaunched MYFEMBREE ® (relugolix/estradiol/norethindrone acetate) in Canada. In June 2024, ...
GUD:CC - Knight Therapeutics Inc. places No. 384 on The Globe and Mail's seventh annual ranking of Canada's Top Growing Companies

MONTREAL, Sept. 26, 2025 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX:GUD) (“Knight” or “the Company”) is pleased to announce it has ranked No. 384 on the 2025 Report on Business magazine’s ranking of Canada’s Top Growing Companies. Canada’...

GUD:CC - Knight Therapeutics Reports Second Quarter 2025 Results

Achieved record-high quarterly revenues since inception Increased 2025 financial guidance MONTREAL, Aug. 07, 2025 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) ("Knight" or “the Company”), a pan-American (ex-US) specialty pharmaceutical company, today rep...

GUD:CC - Expected Canadian Company Earnings on Thursday, August 7th, 2025

Calfrac Well Services Ltd. (CFW:CA) is expected to report $0.14 for Q2 2025 Jamieson Wellness Inc. (JWEL:CA) is expected to report $0.43 for Q2 2025 Strathcona Resources Ltd. (SCR:CA) is expected to report $0.67 for Q2 2025 Stella-Jones Inc. (SJ:CA) is expected to report $1.84 for Q2 ...
GUD:CC - Expected earnings - Knight Therapeutics Inc.

Knight Therapeutics Inc. (GUD:CA) is expected to report $0.03 for Q2 2025

GUD:CC - Knight Therapeutics Announces Regulatory Submission of CREXONT® (Carbidopa and Levodopa) Extended-Release Capsules in Mexico

MONTREAL, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc., (TSX: GUD) ("Knight") a pan-American (ex-USA) specialty pharmaceutical company, announced today that its Mexican affiliate, Grupo Biotoscana de Especialidad S.A. de C.V., has submitted a marketing authorization application for ...

GUD:CC - Knight Therapeutics and Incyte Amend Supply and Distribution Agreement to Add Retifanlimab and Axatilimab in Latin America

MONTREAL, Aug. 04, 2025 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc., (TSX: GUD) ("Knight") a pan-American (ex-USA) specialty pharmaceutical company, announced today that it has expanded its existing relationship and amended its agreement with Incyte Biosciences International Sàrl, the Swiss...
GUD:CC - Notice of Knight Therapeutics' Second Quarter 2025 Results Conference Call

MONTREAL, Aug. 01, 2025 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) (“Knight”), a pan-American (ex-USA) specialty pharmaceutical company, will release its second quarter 2025 financial results on Thursday, August 7, 2025 prior to market opening. Following the release, Kn...

GUD:CC - Knight Therapeutics Announces Regulatory Supplemental Submission of MINJUVI® (tafasitamab) for Follicular Lymphoma in Brazil

MONTREAL, July 31, 2025 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc., (TSX: GUD) ("Knight") a pan-American (ex-USA) specialty pharmaceutical company, announced today that its Brazilian affiliate, United Medical Ltda., has submitted a supplemental application to ANVISA, the Brazilian health regula...

GUD:CC - Knight Therapeutics Announces Filing of New Drug Submission for CREXONT® (Carbidopa and Levodopa) Extended-Release Capsules in Canada

MONTREAL, July 18, 2025 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc., (TSX: GUD) ("Knight") a pan-American (ex-USA) specialty pharmaceutical company, announced today that Knight's New Drug Submission (NDS) for CREXONT ® has been accepted for review by Health Canada. CREXONT ® ...
Previous 10 Next 10